Diagnostic Performance of LI-RADS Version 2018 for Evaluation of Pediatric Hepatocellular Carcinoma
- PMID: 33620289
- DOI: 10.1148/radiol.2021203559
Diagnostic Performance of LI-RADS Version 2018 for Evaluation of Pediatric Hepatocellular Carcinoma
Abstract
Background The Liver Imaging Reporting and Data System (LI-RADS) has standardized the evaluation of adult but not pediatric hepatocellular carcinoma (HCC). Purpose To evaluate the performance of LI-RADS version 2018 for diagnosis of pediatric HCC. Materials and Methods This multi-institution retrospective study evaluated all available dynamic CT and/or MRI scans of pediatric (≤18 years) HCC from five institutions between July 2009 and April 2019. The control group included an equal number of other enhancing hepatic lesions. Blinded to final diagnosis, three radiologists independently applied LI-RADS version 2018 criteria. The reference standard was pathologic examination or more than 1 year follow-up. Sensitivity and specificity of LI-RADS were computed using a dichotomous classification of LR-1, LR-2, or LR-3 versus LR-4, LR-5, LR-TIV (tumor in vein), or LR-M (probably or definitely malignant but not HCC-specific) for predicting hepatic malignancy in the entire cohort and in patients at risk for HCC. Results The cohort consisted of 116 children: 58 with HCC (mean age, 12 years ± 5; 31 girls) and 58 with other enhancing hepatic masses (mean age, 12 years ± 5; 42 girls). Frequencies of major criteria in classic HCC for the three readers were as follows: nonrim arterial phase hyperenhancement, 49%-62% (19-24 of 39 patients); nonperipheral "washout," 36%-59% (14-23 of 39 patients); and enhancing "capsule," 28%-38% (11-15 of 39 patients). For the full cohort, the sensitivity of LR-4, LR-5, LR-TIV, or LR-M for malignancy among the three readers ranged from 85% (95% CI: 76, 94) to 88% (95% CI: 80, 96); specificity of LR-1, LR-2, or LR-3 for benignity ranged from 54% (95% CI: 40, 68) to 70% (95% CI: 57, 83). In the at-risk subgroup, sensitivity ranged from 58% (95% CI: 36, 80) to 68% (95% CI: 48, 89); specificity ranged from 56% (95% CI: 37, 74) to 63% (95% CI: 45, 81). All lesions categorized as LR-TIV (n = 10-13) were HCCs. Conclusion Liver Imaging Reporting and Data System version 2018 had moderate sensitivity but low specificity for the diagnosis of pediatric hepatocellular carcinoma (HCC), which had low frequencies of the major criteria used for adult HCC diagnosis. © RSNA, 2021 See also the editorial by Paltiel in this issue.
Comment in
-
LI-RADS Version 2018 Is of Limited Use in the Diagnosis of Hepatocellular Carcinoma in Children.Radiology. 2021 Apr;299(1):200-201. doi: 10.1148/radiol.2021204480. Epub 2021 Feb 23. Radiology. 2021. PMID: 33625282 No abstract available.
Similar articles
-
Hepatocellular Carcinoma versus Other Hepatic Malignancy in Cirrhosis: Performance of LI-RADS Version 2018.Radiology. 2019 Apr;291(1):72-80. doi: 10.1148/radiol.2019181995. Epub 2019 Jan 29. Radiology. 2019. PMID: 30694166
-
Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease.Eur Radiol. 2024 Dec;34(12):7622-7631. doi: 10.1007/s00330-024-10846-w. Epub 2024 Jul 1. Eur Radiol. 2024. PMID: 38951191
-
Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.AJR Am J Roentgenol. 2020 Nov;215(5):1085-1092. doi: 10.2214/AJR.20.22772. Epub 2020 Sep 2. AJR Am J Roentgenol. 2020. PMID: 32877248
-
Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy-A Systematic Review.Gastroenterology. 2019 Mar;156(4):976-986. doi: 10.1053/j.gastro.2018.11.020. Epub 2018 Nov 13. Gastroenterology. 2019. PMID: 30445016
-
CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.J Am Coll Radiol. 2020 Oct;17(10):1199-1206. doi: 10.1016/j.jacr.2020.06.005. Epub 2020 Jul 5. J Am Coll Radiol. 2020. PMID: 32640250
Cited by
-
Review on Pediatric Malignant Focal Liver Lesions with Imaging Evaluation: Part I.Diagnostics (Basel). 2023 Nov 29;13(23):3568. doi: 10.3390/diagnostics13233568. Diagnostics (Basel). 2023. PMID: 38066809 Free PMC article. Review.
-
Can Dynamic Contrast-Enhanced MRI Be Used to Differentiate Hepatic Hemangioma from Other Lesions in Early Infancy?Indian J Radiol Imaging. 2024 Apr 21;34(4):612-619. doi: 10.1055/s-0044-1785208. eCollection 2024 Oct. Indian J Radiol Imaging. 2024. PMID: 39318559 Free PMC article.
-
Differentiating malignant and benign focal liver lesions in children using CEUS LI-RADS combined with serum alpha-fetoprotein.World J Gastroenterol. 2022 Jun 7;28(21):2350-2360. doi: 10.3748/wjg.v28.i21.2350. World J Gastroenterol. 2022. PMID: 35800178 Free PMC article.
-
MRI major and ancillary features of LI-RADS for diagnosis of pediatric malignant liver tumors.Eur Radiol. 2025 Jun 25. doi: 10.1007/s00330-025-11775-y. Online ahead of print. Eur Radiol. 2025. PMID: 40560413
-
Feasibility of large language models for CEUS LI-RADS categorization of small liver nodules in patients at risk for hepatocellular carcinoma.Front Oncol. 2024 Dec 18;14:1513608. doi: 10.3389/fonc.2024.1513608. eCollection 2024. Front Oncol. 2024. PMID: 39744002 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous